The Medicines Co. Newsletter
-
STAT+: ARCH, Medicines Co. veterans raise $290 million for in-licensed obesity drugs
18 Apr 2024 15:15 GMT
… veterans from Pfizer and The Medicines Company on its team, led the …
-
Mitsui and Rohto to buy US$594m Singapore-based Chinese medicines company Eu Yan Sang
05 Apr 2024 06:44 GMT
SINGAPORE, April 5 ― Japan's Mitsui & Co said yesterday it had teamed up with Rohto Pharmaceutical Co, to buy Eu Yan Sang International in a deal valuing the Singapore-based traditional Chinese medicines firm at S$800 million (RM2.8 billion).
…
-
Mitsui and Rohto to buy $594 million Chinese medicines company Eu Yan Sang
04 Apr 2024 10:12 GMT
SINGAPORE (Reuters) – Japan’s Mitsui & Co said on Thursday it had teamed up with Rohto Pharmaceutical Co to buy Eu Yan Sang International in a deal valuing the Singapore-based traditional Chinese medicines firm at S$800 million ($594 million).
Mitsui …
-
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
24 Apr 2024 02:54 GMT
… Novartis
Novartis is an innovative medicines company. Every day, we work to …
-
FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery
23 Apr 2024 20:54 GMT
… oncolytic virus for NMIBC. Genetic medicines company enGene, which became public last …
-
Aptamer Group signs material agreement with genetic medicines company
20 Feb 2024 09:31 GMT
publication date: Feb 20, 2024
|
author/source: Aptamer Group
Optimer binders will be developed to support targeted genetic medicines to specific cell types
Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life …
-
Novartis names ex-BMS CEO Caforio as chair amid strong Q1
23 Apr 2024 14:33 GMT
… successfully transformed into a global medicines company with strong capabilities across R …
-
Novartis nominates former Bristol Myers CEO Giovanni Caforio as its new chair. Will M&A deals follow?
23 Apr 2024 11:41 GMT
… transforming BMS into “a global medicines company with strong capabilities across R … became a pure-play innovative medicines company after separating the generics maker … .7 billion buyout of The Medicines Company was among Novartis’ largest in …
-
Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform
23 Apr 2024 11:19 GMT
… Medicines, a clinical-stage genetic medicines company developing treatments for rare diseases …
-
Encoded Therapeutics Provides Pipeline Updates From Its Vector Engineering Platform Ahead of Four Preclinical Presentations at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
23 Apr 2024 11:19 GMT
… is a clinical-stage genetic medicines company developing potentially disease-modifying therapies …